Ontario study maps 24 medication chains that can turn side effects into new prescriptions
A large Ontario analysis has put a number on a problem clinicians see every day but often fail to name: a prescribing cascade starts when a medication side effect is mistaken for a separate illness, then treated with another drug. In older adults, where polypharmacy is common and symptoms rarely have a single cause, that sequence can quickly become self-reinforcing. The new population-level study identified 24 commonly observed cascades with enough frequency and signal strength to warrant concern, including combinations involving statins, iron supplements, and other widely used therapies. The findings carry a blunt clinical message: the next prescription may be compensating for a problem created by the last one.
One example is easy to picture at the bedside. NSAIDs can raise blood pressure; if the resulting increase is treated as newly developed hypertension, clinicians may add an antihypertensive rather than reconsider the pain regimen. In that scenario, the blood pressure drug is not solving a primary cardiovascular disease process. It is masking a medication adverse effect and making the treatment list longer.
Older adults are especially exposed to this kind of diagnostic drift. Multiple chronic diseases, overlapping symptoms, and long medication lists make it harder to connect a new complaint with a recently started drug. A patient develops edema, constipation, fatigue, cough, dizziness, or blood pressure changes, and the symptom is often managed in isolation. The original medication stays in place, the new prescription is added, and the cascade continues.
How the Ontario team separated common use from clinically meaningful harm
The study was published in BMJ and led by Dr. Paula Rochon, Director of Research at the Weston and O’Born Center for Mature Women’s Health at Sinai Health in Toronto. The work drew on an interdisciplinary group of experts in medication prescribing and geriatric medicine, with collaborators from the United States, Belgium, Italy, Israel, and Ireland. Sinai Health researchers included Drs. Vasily Giannakeas, Nathan Stall, and Christina Reppas-Rindlisbacher, alongside research staff Wei Wu and Joyce Li.
The project built on earlier work in which 12 international panelists in internal medicine, geriatric medicine, and clinical pharmacology helped generate a list of 65 potentially inappropriate prescribing cascades. The new analysis then compared those candidate cascades with population-level prescription data from ICES, Ontario’s health data institute. Each potential cascade was evaluated using three dimensions: how often the first medication was prescribed, how often a second drug followed, and how strongly the two prescriptions appeared linked in real-world use.
That approach produced a narrower list of 24 cascades that were both common and plausibly harmful. The distinction matters because an unusual interaction seen only sporadically does not necessarily tell a system-level story. A cascade that appears repeatedly across a population does. It suggests a repeated failure in clinical reasoning, medication review, or communication between prescriber and patient.
Dr. Rochon framed the problem as a communication gap that accumulates over time. Patients often do not know which drug was started for which reason, and clinicians may not revisit the original indication when a new symptom appears. The result is a chain of care decisions built on incomplete context rather than on the full medication history.
A single medication list is not enough.
Why mature women may absorb more of the harm
The findings may carry special weight for mature women, who tend to live longer with chronic illness, receive more medication therapy, and experience more adverse drug events over the life course. Each added drug increases the chances that a side effect will be mistaken for a new diagnosis. When that happens, the patient does not just accumulate pills; she accumulates diagnostic uncertainty.
The clinical implications extend beyond inconvenience. Unnecessary prescribing can expose older adults to additional adverse effects, drug-drug interactions, and more complicated treatment routines. It can also drive avoidable health care use and cost, particularly when the new prescription triggers further monitoring, dose changes, or follow-up visits. In geriatric medicine, the harm is rarely confined to one organ system. A medication added for one symptom can worsen cognition, balance, appetite, bowel function, or blood pressure control elsewhere.
The study points toward two practical responses. First, medication reviews need to ask when each drug was started, why it was prescribed, and whether a new symptom tracks with a known adverse effect of an existing therapy. Second, systems of care need to help clinicians see patterns that are easy to miss in a busy visit. Those patterns often reveal themselves only when the chronology is reconstructed.
Pharmacists and automated alerts could interrupt the cascade earlier
The researchers argue that technology could help detect these patterns before they solidify into routine prescribing. Automated clinical decision support tools could flag a possible cascade when a new drug appears to match a known side effect of an existing medication. At the point of care, such alerts could prompt a pause: is this a new disease, or is it the predictable result of an earlier prescription?
Pharmacists may be especially well positioned to catch those signals. Their training emphasizes medication reconciliation, adverse effect recognition, and drug-drug interaction review, all of which are central to identifying a cascade. Bringing pharmacists more directly into prescribing decisions could surface patterns that otherwise remain hidden in fragmented care.
The study does not suggest that every new symptom is medication-related, or that every added therapy is inappropriate. It does show that some common prescription chains are frequent enough to deserve systematic scrutiny. In older adults, and especially in women with layered chronic disease, a careful review of timing, indication, and symptom onset may be the difference between treating a disease and perpetuating a drug-induced problem. The remaining challenge is operational: getting those questions asked before the second prescription becomes the new normal.